
NovoCure Q2 Revenue Jumps 6 Percent
NovoCure (NVCR -23.93%), the oncology device firm advancing Tumor Treating Fields therapy, released its second quarter 2025 results on July 24, 2025. GAAP revenue totaled $158.8 million in Q2 2025, an increase of 6% year over year and surpassing the $154. …